ING Groep NV Increases Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

ING Groep NV grew its position in Henry Schein, Inc. (NASDAQ:HSIC) by 34.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,163,087 shares of the company’s stock after buying an additional 295,785 shares during the quarter. ING Groep NV owned 0.93% of Henry Schein worth $80,486,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cromwell Holdings LLC increased its position in Henry Schein by 93.4% during the 3rd quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock worth $26,000 after purchasing an additional 170 shares in the last quarter. Versant Capital Management Inc increased its position in Henry Schein by 274.6% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $32,000 after purchasing an additional 335 shares in the last quarter. Venturi Wealth Management LLC increased its position in Henry Schein by 3,347.1% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock worth $41,000 after purchasing an additional 569 shares in the last quarter. Quent Capital LLC increased its position in Henry Schein by 91.2% during the 4th quarter. Quent Capital LLC now owns 677 shares of the company’s stock worth $47,000 after purchasing an additional 323 shares in the last quarter. Finally, City State Bank purchased a new stake in Henry Schein during the 4th quarter worth about $55,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Analysts Set New Price Targets

HSIC has been the subject of a number of recent research reports. Barrington Research lifted their price objective on Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, January 30th. Mizuho initiated coverage on Henry Schein in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price target on the stock. Wells Fargo & Company initiated coverage on Henry Schein in a research note on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target on the stock. StockNews.com raised Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and raised their price target for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.09.

Henry Schein Stock Performance

NASDAQ HSIC opened at $77.83 on Thursday. The firm has a market capitalization of $9.70 billion, a P/E ratio of 32.03, a P/E/G ratio of 2.19 and a beta of 0.91. Henry Schein, Inc. has a 1-year low of $63.67 and a 1-year high of $82.63. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The business’s 50-day simple moving average is $74.11 and its 200-day simple moving average is $72.11.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.